Open Access

PTPN11 hypomethylation is associated with gastric cancer progression

  • Authors:
    • Lele Xu
    • Cong Zhou
    • Ranran Pan
    • Junjian Tang
    • Jinzhi Wang
    • Bin Li
    • Tianyi Huang
    • Shiwei Duan
    • Chunfang Xu
  • View Affiliations

  • Published online on: January 7, 2020     https://doi.org/10.3892/ol.2020.11250
  • Pages: 1693-1700
  • Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Protein tyrosine phosphatase non‑receptor type 11 (PTPN11) encodes the tyrosine phosphatase SHP‑2 that is overexpressed in gastric cancer (GC). In the present study, the association of PTPN11 methylation levels with the incidence of GC and its correlation with SHP‑2 overexpression were investigated. The methylation levels of PTPN11 in tumor and adjacent normal tissues of 112 GC patients were assessed by quantitative methylation specific PCR (qMSP). The Cancer Genome Atlas (TCGA) public database was used to analyze the association between PTPN11 methylation and PTPN11 expression. Survival analyses were conducted in order to evaluate the prognostic value of PTPN11 methylation for GC. The results of the qMSP analysis indicated that the methylation levels of PTPN11 in GC tumor tissues were significantly decreased compared with those noted in the normal adjacent tissues (mean with standard deviation: 40.91±26.33 vs. 51.99±37.37, P=0.007). An inverse correlation between PTPN11 methylation levels and PTPN11 mRNA expression levels (P=4x10‑6, r=‑0.237) was noted. Subgroup analyses indicated that the association of PTPN11 hypomethylation with the incidence of GC was specific to male subjects (P=0.015), heavy drinking patients (P=0.019), patients with poor tumor differentiation (P=0.010) and patients with tumor node and metastasis (TNM) stage III+IV (P=0.008). Kaplan‑Meier analyses and log‑rank test suggested that PTPN11 hypomethylation was not associated with GC patient overall survival (P=0.605) and recurrence (P=0.485), although it could predict the recurrence of GC patients up to and including 60 years (≤60, P=0.049). The results indicated that PTPN11 levels were hypomethylated in GC patients. TCGA data analysis suggested that PTPN11 hypomethylation could cause an upregulation in the transcription levels of PTPN11. Although, this may explain the pattern of SHP‑2 overexpression in GC, additional studies are required to verify this hypothesis. The association of PTPN11 hypomethylation with GC incidence may be specific to male patients, heavy drinking patients, patients with poor tumor differentiation and patients with TNM stage of III+IV. PTPN11 hypomethylation can be considered a biomarker for the recurrence of GC patients with an age of 60 years or lower.

Related Articles

Journal Cover

March 2020
Volume 19 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Xu, L., Zhou, C., Pan, R., Tang, J., Wang, J., Li, B. ... Xu, C. (2020). PTPN11 hypomethylation is associated with gastric cancer progression. Oncology Letters, 19, 1693-1700. https://doi.org/10.3892/ol.2020.11250
MLA
Xu, L., Zhou, C., Pan, R., Tang, J., Wang, J., Li, B., Huang, T., Duan, S., Xu, C."PTPN11 hypomethylation is associated with gastric cancer progression". Oncology Letters 19.3 (2020): 1693-1700.
Chicago
Xu, L., Zhou, C., Pan, R., Tang, J., Wang, J., Li, B., Huang, T., Duan, S., Xu, C."PTPN11 hypomethylation is associated with gastric cancer progression". Oncology Letters 19, no. 3 (2020): 1693-1700. https://doi.org/10.3892/ol.2020.11250